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Abstract
Background: Drug susceptibility testing (DST) remains an important concern for implementing treatment of MDR
tuberculosis patients. Implementation of molecular tests for drug resistance identification would facilitate DST
particularly in developing countries where culturing is difficult to perform. We have characterized multidrug
resistant strains in Cambodia using MDTDRsl tests, drug target sequencing and phenotypic tests.
Methods: A total of 65 non-MDR and 101 MDR TB isolates collected between May 2007 and June 2009 were
tested for resistance to fluoroquinolones and aminoglycosides/cyclic peptides using the GenoType® MTBDRsl assay
and gene sequencing. Rifampicin resistance (RMP-R) was tested using gene sequencing and genotyping was
assessed by spoligotyping.
Results: A total of 95 of the 101 MDR strains were confirmed to be RMP-R by rpoB gene sequencing. Fourteen of
the 101 MDR isolates (14%) carried a gyrA mutation associated with fluoroquinolone-resistance (FQ-R) (detected by
the MTBDRsl assay and sequencing) compared with only 1 (1.5%) of the 65 non-MDR strains. Only 1 (1%) of the
MDR isolates was found to be XDR TB. The MDR group contained a higher proportion of Beijing or Beijing like
strains (58%) than the non MDR group (28%). This percentage is higher in MDR FQ-R strains (71%).
Conclusions: The new GenoType® MTBDRsl assay combined with molecular tests to detect RMP-R and isoniazid
resistance (INH-R) represents a valuable tool for the detection of XDR TB. In Cambodia there is a low rate of XDR
amongst MDR TB including MDR FQ-R TB. This suggests a low association between FQ-R and XDR TB. Strain
spoligotyping confirms Beijing strains to be more prone to accumulate antibiotic resistance.
Background
The World Health Organization (WHO) estimated that
there were 0.5 million cases of multi-drug-resistant (MDR)
tuberculosis (TB) in 2007. Only 8.5% of the estimated glo-
bal total of smear-positive cases of MDR-TB were notified.
By the end of 2008, 55 countries and territories had
reported at least one case of extensively drug-resistant TB
(XDR-TB) which are defined as MDR strains that are also
resistant to a fluoroquinolone (FQ) and at least one
second-line injectable agent (amikacin (AM), kanamycin
(KM) and/or capreomycin (CM)) [1].
The WHO underlines the absolute necessity to rapidly
scale up the diagnosis and effective disease management
of MDR-TB and highlights the problem of access to
drug susceptibility testing (DST) for second-line drugs
(SLD). Indeed, only nine of the 22 high burden coun-
tries (HBCs), who account for 80% of incident TB cases,
had access to second-line DST [2].
In 2007, Cambodia with a population of 14.4 million,
ranked 21st among the HBCs for TB. The incidence of
all forms of TB in this country in 2007 was estimated at
495/100,000 population with a mortality rate at 89/
100,000 population [1]. The directly observed therapy
strategy (DOTS) has covered 100% of the TB cases for
more than 10 years, with 93% treatment success and the
number of sputum-smear positive MDR-TB cases (in
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2007) estimated to be 94 cases [1]. The incidence of
MDR-TB appears to have remained relatively low. In
2001, a study of drug resistance carried out by the
National Tuberculosis Control Program of Cambodia
reported the absence of MDR among new cases and a
rate of 0.4% of MDR-TB among all TB cases [3]. Never-
theless, a study undertaken between March 2003 and
February 2005 found a rate of 5.1% of MDR-TB among
HIV co-infected tuberculosis patients in Phnom Penh
[4]. In 2007, the HIV prevalence among TB patients was
7.8% and 46% of TB relapses were MDR (data not pub-
lished). It is essential that TB remains under active sur-
veillance in Cambodia and MDR-TB diagnosis must be
further developed. However, until 2011, no laboratory in
Cambodia had second-line DST capability. The aim of
this retrospective study was to evaluate the prevalence
of XDR, among MDR strains. Rifampicin-resistance
(RMP-R) was confirmed using rpoB gene sequencing.
The GenoType® MTBDRsl assay was used for detection
of resistance to FQ, and aminoglycosides/cyclic peptides
(AG/CP) using gyrA, and rrs target genes. Spoligotyping
was used to determine the rate of strain transmission
among the MDR population.
Methods
Strains
MDR strains were collected at the Institut Pasteur of
Cambodia between May 2007 and June 2009 from all
patients diagnosed with MDR TB after drug susceptibil-
ity testing. Non MDR strains were selected randomly
during the same period. In total, 65 non MDR and 101
MDR M. tuberculosis strains were isolated in the Myco-
bacteriology Laboratory at the Institut Pasteur du Cam-
bodge (IPC, Phnom Penh). DST for first-line TB drugs
was performed using the BD MGIT reading manual
method before May 2009 and by the MGIT Bactec 960
method after this date. DNA was extracted from the iso-
lates and used for sequencing, MTBDRsl assay and
spoligotyping.
GenoType® MTBDRsl assay
The GenoType® MTBDRsl assay provided by BIO-
CENTRIC, Bandol, France, was used to determine resis-
tance to FQ, and AM/CM. Tests were performed
according to the manufacturer’s instructions.
DNA sequencing of the rpoB, gyrA, rrs genes
Genes were amplified by PCR and then sequenced using
a BigDyeTerminator kit and an ABI Prism model 3100
DNA sequencer. Primer sequences are given in Table 1.
Spoligotyping
Spoligotyping was performed as previously described [5].
Results
A total of 101 MDR strains and 65 non MDR strains
previously characterized by conventional DST were
investigated in this study. Eighty-six MDR strains were
also resistant to streptomycin (SM). Results are pre-
sented in tables 2 and 3.
RMP-R
A total of 95 out of 101 (94%) MDR strains with a
RMP-R phenotype carried a mutation known to confer
resistance in the core region of the rpoB genes (table 2).
The codons most frequently involved were codon 516
(18/101 = 18%), codon 526 (22/101 = 22%) and codon
531 (47/101 = 47%). All of these mutations can be
detected by the GenoType® MTBDRplus assay. Eighty-
three strains showed a single mutation (codons involved:
516, 526, 529, 531 and 533) and 3 had a repetition of
codon 514, which is associated with the mutation
A532V. Ten strains displayed several mutations (or a
deletion for one strain) with at least one known to be
associated with RMP resistance. One strain showed a
previously un-published mutation (L524W) associated
with deletion of codon 526. In six strains that were phe-
notypically RMP-R, the sequence of the core region of
rpoB was identical to the wild type. Because most RMP-
R strains are known to be isoniazid resistant (INH-R),
molecular INH resistance was not checked to confirm
phenotypic isoniazid resistance and RMP-R strains were
considered as MDR strains.
FQ-R
Mutations known to be associated to FQ-R were found in
14 out of 101 MDR strains (14%) and 1 out of the 65 non
MDR strains (1.5%). The MTBDRsl assay detected all 14
FQ-R mutations that were confirmed by gyrA sequencing.
The codons involved were 94 (gac D94A gcc, n = 7; gac
D94G ggc, n = 5) and 90 (gcg A90V gtg, n = 2) (table 2).
In 3 of these 14 strains, a superposition of nucleotides was
observed suggesting that they were a mixture of wild type
and mutant populations. All the strains were shown to
carry a mutation at codon 21 [6] and 95 [7] of the gyrA
gene. This polymorphism is not associated with resistance.
The FQ-R group contained a higher proportion of Beijing
strains identified by spoligotyping (10/14, 71%) than the
FQ-S group (47/87, 54%).
rrs gene
The rrs gene was sequenced in 95 strains to identify
resistance to AM, KM and/or CM. For 6 strains,
sequencing data was not interpretable because of bacter-
iological contamination. The MTBDRsl assay detected
only one strain with a1401 g mutation in the rrs gene.
No other strain had a mutation at codon 1401, 1402 or
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Table 1 Primers used for detection of antibiotic resistance
Antibiotic Gene Primers Product size (bp)
Rifampicin rpoB TR1 (5’-TACGGTCGGCGAGCTGATCC-3’) 411
TR2 (5’-TACGGCGTTTCGATGAACC-3’)
Fluoroquinolones gyrA gyrA-F (5’-GATGACAGACACGACGTTGC-3’) 398
gyrA-R (5’-GGGCTTCGGTGTACCTCAT-3’)
Kanamycin/Amikacin rrs Rrs F (5’-AAACCTCTTTCACCATCGAC-3’) 1329
Rrs R (5’-GTATCCATTGATGCTCGC-3’).
bp: base pair.
Table 2 Results of phenotypic testing, sequencing, MTBDRsl and spoligotyping
MDR strains
Number of strains DST Phenotype Molecular testing Spoligotype
RMP FQ KM/AM
rpoB gyrA MTBDRsl rrs (1401, 1402, 1484) MTBDRsl
1 INH, RMP, SM S531L A90V r a1401g r EAI2-NTB
1 INH, RMP, SM D516V A90V mixed wt r wt s Beijing
1 INH, RMP, SM S531L D94A r nd s Beijing
2 INH, RMP, SM S531L D94A r wt s Beijing
1 INH, RMP, SM H526Y D94A r wt s Beijing
1 INH, RMP, SM S531L D94A r wt s Beijing
1 INH, RMP, SM S531L D94A r wt s Beijing
1 INH, RMP, SM L533P D94A mixed wt r wt s Beijing
1 INH, RMP, SM D516V D94G r wt s Beijing
1 INH, RMP, SM H526D D94G r wt s Beijing
1 INH, RMP, SM S531L D94G r wt s EAI1_SOM
1 INH, RMP, SM S531L D94G r wt s U
1 INH, RMP, SM S531L D94G mixed wt r wt s U
1 INH, RMP S531L wt s wt s Beijing
1 INH, RMP S531L wt s wt s Beijing
1 INH, RMP S531L wt s wt s Beijing
1 INH, RMP, SM H526N L533P wt s wt s Beijing
1 INH, RMP, SM H526R wt s wt s Beijing
1 INH, RMP, SM R529Q mixed wt wt s wt s Beijing
1 INH, RMP, SM D516G S531L wt s wt s Beijing
1 INH, RMP, SM D516V wt s wt s Beijing
1 INH, RMP, SM D516V wt s wt s Beijing
1 INH, RMP, SM D516V wt s wt s Beijing
1 INH, RMP, SM D516V wt s wt s Beijing
1 INH, RMP, SM D516V wt s wt s Beijing
1 INH, RMP, SM D516V mixed wt wt s wt s Beijing
1 INH, RMP, SM D516V mixed wt; S531L wt s wt s Beijing
1 INH, RMP, SM insertion ttc 514; A532V wt s nd s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
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Table 2 Results of phenotypic testing, sequencing, MTBDRsl and spoligotyping (Continued)
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
2 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM wt wt s wt s Beijing
1 INH, RMP, SM S512N T525T H526P L527Q wt s wt s Beijing
1 INH, RMP, SM H526D wt s wt s Beijing
1 INH, RMP, SM H526Y wt s wt s Beijing
1 INH, RMP, SM H526Y wt s wt s Beijing
2 INH, RMP, SM H526N L533P wt s wt s Beijing
1 INH, RMP, SM H526R wt s wt s Beijing
1 INH, RMP, SM H526R wt s wt s Beijing
1 INH, RMP, SM L533P wt s wt s Beijing
1 INH, RMP, SM D516V mixed wt; S531L wt s wt s Beijing
1 INH, RMP, SM insertion ttc 514 wt s wt s Beijing
1 INH, RMP, SM insertion ttc 514 wt s wt s Beijing
2 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
2 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing
1 INH, RMP, SM L524W T525P del 526 wt s wt s Beijing
1 INH, RMP, SM wt wt s wt s Beijing
1 INH, RMP, SM S531L wt s wt s Beijing-like
1 INH, RMP, SM wt wt s wt s Beijing-like
1 INH, RMP del 518 wt s wt s EAI1_SOM
1 INH, RMP S531L wt s wt s EAI1_SOM
1 INH, RMP wt wt s nd s EAI1_SOM
1 INH, RMP, SM S531L wt s wt s EAI1_SOM
1 INH, RMP, SM H526D wt s wt s EAI1_SOM
1 INH, RMP, SM S531L wt s nd s EAI1_SOM-EAI2
1 INH, RMP, SM S531L wt s wt s EAI4_VNM
1 INH, RMP, SM H526D wt s wt s EAI5
2 INH, RMP, SM D516Q Q517N del 518 wt s wt s EAI5
1 INH, RMP, SM S531L wt s nd s EAI5
1 INH, RMP L533P wt s wt s EAI5
1 INH, RMP S531L wt s wt s EAI5
1 INH, RMP L533P wt s wt s U
1 INH, RMP D516V wt s wt s U
1 INH, RMP, SM D516V mixed wt wt s wt s U
1 INH, RMP, SM H526D wt s wt s U
2 INH, RMP, SM H526D wt s wt s U
1 INH, RMP, SM S531L wt s wt s U
1 INH, RMP, SM S531L wt s wt s U
1 INH, RMP H526D mixed wt wt s wt s Unknown
1 INH, RMP S531L wt s wt s Unknown
1 INH, RMP S531L wt s wt s Unknown
1 INH, RMP wt wt s wt s Unknown
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1484, which are all known to be associated with resis-
tance to AM, KM and CM. Among the MDR strains, all
except one of the 14 FQ-R strains were found to be
AM-S. The AM-R strain was also FQ-R, thus, this single
XDR strain represents 1% of the MDR population.
Strain diversity
Spoligotyping results showed that the majority of MDR
strains belonged to the Beijing family (57/101, 56%) or
were Beijing like (2/101, 2%). This percentage is higher in
MDR FQ-R strains (10/14, 71%). This confirms that Beij-
ing strains are more prone to accumulate antibiotic resis-
tances. The other families were: U (10/101), EA15 (6/
101), EAI1_SOM (6/101), EAI1_SOM-EA12 (1/101),
EA12-NTB (1/101), EA14-VNM (1/101), ZERO (1/101)
and 16 Unknown profiles. In contrast, only 17 Beijing
and 1 Beijing like out of 65 non MDR strains (28%) were
identified as such. The other families were: U (3/65),
EA15 (13/65), EAI_SOM (2/65), EAI1_SOM (6/65),
EA12_MANILLA (2/65), H3 (1/65), and 20 Unknown
profiles. MDR strain comparisons using spoligotype pro-
files and target gene mutations allowed us to differentiate
74/101 strains indicating that they are not epidemiologi-
cally related. The other MDR strains were grouped as fol-
lows: 27 strains were grouped into 10 pairs (6 pairs of
Beijing and 4 non Beijing) and one group of three Beijing
and one group of four Beijing strains.
Discussion
This study analyzed resistance of Cambodian MDR-TB
strains to major anti-tuberculosis drugs.
Unpublished data showing that 46% of TB relapses in
Cambodia are MDR is consistent with previous reports
from the Central African Republic [8], Japan [9], and
South Africa [10].
RMP-R was confirmed with rpoB core region sequen-
cing in 94% of MDR strains. This agrees with other stu-
dies showing that some RMP-R strains carry a wild type
rpoB core region sequence [11]. rpoB core region muta-
tions were in the hot spot positions associated with
RMP-R strains [12,13]. We observed a high number of
MDR strains carrying several rpoB mutations. This may
suggest a stepwise process of additive mutations (as
described for FQ-R) that could generate higher levels of
resistance to RMP [14-16].
To evaluate the number of XDR strains among MDR
strains we identified mutations in gyrA and rrs genes
which are associated with FQ resistance and AG/CM
resistance respectively. Our study found that 14% of clini-
cal MDR-TB isolates were FQ resistant. This rate is lower
than that found in other studies of MDR-TB in Southern
Asia: Taiwan 22.2% [17] or 42.8% using phenotypic DST;
Shanghai 25.1% [18] and the Philippines 17% [19] or
51.4% [20]. However, these figures are much higher than
those found on other continents (4.1% in MDR-TB in the
United States and Canada [21] and 4.3% in MDR-TB in
Russia [22]). Only one of the MDR FQ-R strains was
AM-R. Therefore, only 1% of MDR strains are identified
as XDR strains. This shows that identification of only
gyrA FQ-R mutations is not a strong indication of an
XDR phenotype.
Previous studies [23,24] showed a high level of con-
cordance between MTBDRsl and phenotypic tests: I.E.
90.2% and 75.6% respectively. In this study, we had no
access to phenotypic tests for FQ. MTBDRsl and
sequencing data of gyrA are 100% concordant and these
techniques identified 14% FQ-R in MDR strains. This
FQ-R rate may have been underestimated because of the
unavailability of FQ phenotypic testing in Cambodia. FQ
resistance is most often associated with gyrA mutations
Table 2 Results of phenotypic testing, sequencing, MTBDRsl and spoligotyping (Continued)
1 INH, RMP wt wt s wt s Unknown
1 INH, RMP, SM H526Y wt s wt s Unknown
1 INH, RMP, SM H526D R529Q wt s wt s Unknown
2 INH, RMP, SM S531L wt s wt s Unknown
1 INH, RMP, SM S531L wt s wt s Unknown
1 INH, RMP, SM H526Y wt s wt s Unknown
1 INH, RMP, SM D516V wt s wt s Unknown
1 INH, RMP, SM D516V wt s nd s Unknown
1 INH, RMP, SM S531L wt s wt s Unknown
1 INH, RMP, SM S531L wt s wt s Unknown
1 INH, RMP, SM S531L wt s wt s Unknown
1 INH, RMP, SM D516G wt s nd s ZERO
INH isoniazid, RMP rifampicin, SM streptomycin.
AM amikacin, FQ fluoroquinolones, KM kanamycin.
wt wild type, s susceptible, r resistant, nd not determined.
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[25,26] and more particularly mutations at codons 94
and 90. This was the case in our study. The percentage
of FQ-R M. tuberculosis clinical isolates with gyrA muta-
tions have been reported to be between 70% and 90%
[23]. Because we have no access to FQ-R phenotypic
tests, our analysis may have missed a number of cases.
However, as reported before [23,24], in the absence of
phenotypic tests, molecular tests will detect more than
75% of FQ-R cases. Mutations other than those affecting
gyrA and other mechanisms could result in FQ-R,
including: decreased cell-wall permeability to drug,
efflux pumps, drug sequestration or perhaps even drug
inactivation [12,26]. In a small number of cases, FQ-R
could be associated with gyrB mutations and a probable
efflux mechanism [27,28].
FQ has become an essential part of treatment regimens
for MDR tuberculosis [25,26]. Due to their efficacy and
safety, the new generation of FQ’s is even being evaluated
as a first-line medication for tuberculosis [27-29]. Unfor-
tunately, the extensive use of FQ has increased sponta-
neous acquisition of mutations associated with FQ-R. It
has been suggested that routine FQ-R testing in locations
where resistant strains are endemic may be clinically use-
ful by showing a significant correlation between develop-
ment of FQ-R and first-line M. tuberculosis drug
resistance [30]. However, extensive use of FQ would
likely increase MDR tuberculosis treatment failure. As in
other developing countries, problems arise from the
uncontrolled use of antibiotics. However, it is interesting
to note that only 1 out of 14 MDR FQ-R strains is XDR,
thus showing that detection of FQ-R strains cannot be
used as a single marker for the detection of XDR cases.
Additional tests are required to identify XDR cases,
among them molecular tests like MTBDRsl that include
the detection of mutations in gyrA associated to FQ-R
and rrs associated with AM, KM and CM resistance.
Work by other researchers has demonstrated that the
MTBDRsl assay detected 86.7% (39/45) and 100% (5/5)
of phenotypically AM and CM resistant TB strains
[23,24]. The mutation a1401 g was the most prevalent.
The XDR isolate in our study was confirmed to carry
a1401 g mutation in the rrs gene. This result suggests a
low rate of XDR amongst MDR TB in Cambodia (1%) as
compared to countries like India and Taiwan that have
reported rates of 8-15% and 10% respectively [31,32].
This favorable situation could be linked to the implemen-
tation of the DOTS strategy in 1980 by the national TB
control program in Cambodia [3].
Spoligotyping confirmed previous observations that the
Beijing family is prevalent in Asia. The higher proportion
of Beijing spoligotypes in the MDR group (58%) com-
pared with the non MDR group (28%) is consistent with
previous studies demonstrating that strains of the Beijing
genotype more readily acquire resistance mutations than
Table 3 Results of phenotypic testing, sequencing and
spoligotyping
non MDR strains
Number of strains DST Phenotype Sequencing Spoligotype
rpoB gyrA
1 INH, SM wt wt Beijing
3 SM wt wt Beijing
13 no resistance wt wt Beijing
1 no resistance wt wt Beijing-like
1 SM wt wt EAI_SOM
1 no resistance wt V55V EAI_SOM
1 INH wt wt EAI1_SOM
4 no resistance wt wt EAI1_SOM
1 no resistance wt wt EAI1_SOM
1 no resistance wt wt EAI2_MANILLA
1 no resistance wt wt EAI2_MANILLA
1 INH Q513K wt EAI5
1 INH wt wt EAI5
1 INH wt wt EAI5
1 no resistance wt wt EAI5
2 no resistance wt wt EAI5
4 no resistance wt wt EAI5
1 no resistance wt wt EAI5
1 no resistance wt wt EAI5
1 no resistance wt wt EAI5
1 no resistance wt wt H3
1 INH, SM wt wt U
2 no resistance wt wt U
1 INH, SM wt D94A Unknown
1 INH wt wt Unknown
1 INH wt wt Unknown
1 RMP H526Y wt Unknown
1 RMP wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
1 no resistance wt wt Unknown
INH isoniazid, RMP rifampicin, SM streptomycin, wt wild type.
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non-Beijing strains [33-35]. This percentage is increased
in the MDR FQ-R group (71%). Although most of the
spoligotypes had the Beijing profile, no major MDR out-
break by this family has been reported in Cambodia.
Further studies with new markers are warranted to pro-
vide a more accurate picture of the epidemiology of the
Beijing strains in Cambodia.
Conclusions
A molecular study of 101 MDR M. tuberculosis strains in
Cambodia identified only 1 (1%) XDR strain although a
high number of the MDR cases showed FQ-R (14%). The
new GenoType® MTBDRsl assay represents a reliable
tool for the detection of FQ and AG/CAP resistance and
in combination with molecular tests for the detection of
RMP-R and INH-R, XDR TB can potentially be identified
within 1 or 2 days. These tests could provide valuable
information to facilitate the management of patient ther-
apy and the prevention of transmission.
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